Semaglutide Jabs Show Promise in Treating Deadly Heart Failure

Strategic Insights -

A trial involving over 1,145 patients has found that semaglutide, a type of weight-loss jab, can help ease symptoms of heart failure, offering new hope to the hundreds of thousands of Britons affected by the condition. The analysis, presented in the Journal of the American College of Cardiology, discovered that the jab provided significant benefits to both men and women, despite women shedding more weight, losing an average of 9.6% of their body mass compared to 7.2% in men. The study suggests that semaglutide may be addressing an underlying mechanism of heart failure, in addition to the benefits of weight loss.

Key Takeaways:

  • The trial found that semaglutide, known as Ozempic and Wegovy, helped patients with preserved ejection fraction (HFpEF) heart failure, a condition where the heart pumps normally but is too stiff to fill properly.
  • Women shed more weight, losing an average of 9.6% of their body mass, compared to 7.2% in men, but both sexes experienced improved heart failure symptoms.
  • The jab improved symptoms such as shortness of breath, fatigue, and swelling in the legs and feet, and allowed patients to do more exercise.
  • Reduced levels of inflammation were also observed in patients receiving the jab.
  • HFpEF affects around half a million people in the UK, with an annual mortality rate of 10 to 15% and patients typically being hospitalized around once a year.
  • Dr. Sonya Babu-Narayan, associate medical director at the British Heart Foundation, emphasized the "exciting" potential of semaglutide, saying it could have a transformational impact on someone's life.

Statistics:

  • 1,145 patients were involved in the trial.
  • 9.6% avg. weight loss in women.
  • 7.2% avg. weight loss in men.
  • 10-15% annual mortality rate for HFpEF in the UK.
  • 500,000+ people in the UK affected by HFpEF.
  • Patients receiving the jab experienced reduced levels of inflammation.

Sources:

  • Journal of the American College of Cardiology
  • European Congress of Obesity
  • British Heart Foundation
  • The trial involving over 1,145 patients